Subscribe X
Back to Top


May 21, 2019 by Foundation for Excellence in Mental Health Care

Psychiatric Medication Discontinuation and Reduction study data now freely available

The dataset for the Psychiatric Medication Discontinuation and Reduction Study is now freely available through Open ICPSR (Inter-university Consortium for Political and Social Research)

The latest article drawing on the study data was published yesterday in Psychosis, An exploratory analysis of the role of social supports in psychiatric medication discontinuation: Results related to family involvement, authored by Laysha Ostrow, Bevin Croft, Anne Weaver, and Sarah Naeger.

Live & Learn, Inc. explains:

This article explores the role of various groups that may be a source of social support for people who sought to discontinue psychiatric medications. To do this, we conducted data analyses to explore the relationship of social support to discontinuation.

Of all social support groups, only family was significantly associated with medication discontinuation in analysis. Respondents who rated family as helpful in the discontinuation process were less likely to completely discontinue than those who rated family as unhelpful or who reported no family involvement.

Additionally, we observed a statistically significant but nonlinear relationship where respondents who rated their families as either “very supportive” or “very unsupportive” of the decision to discontinue were less likely to meet their original discontinuation goal than those with more neutral ratings.

Clearly, families have an important and complex role in medication decision-making. Efforts to improve the quality of social networks should include family, as should future research, which should address family dynamics surrounding decision-making about psychiatric medication. Additional research on family perspectives about psychiatric medication discontinuation would also be a valuable addition to the literature and might inform family support interventions.

While 1 in 6 Americans take a psychiatric medication for serious mental illness, there is little research on people’s experiences coming off of them. In the first large scale study in the U.S., Live & Learn, Inc., in partnership with researchers at UCLA, UCSF and New York University, began to fill this knowledge gap. It surveyed 250 long-term users of psychiatric medications who had a diagnosis of serious mental illness and chose to discontinue use. The 2016 study, funded by the Foundation for Excellence in Mental Health Care and led by current and former users of psychiatric medications, sought to understand first-hand experiences and strategies of individuals who decided to discontinue psychiatric medications, and either stopped or reduced the use of these medications.

Leave a Reply

Your email address will not be published. Required fields are marked *

This site uses Akismet to reduce spam. Learn how your comment data is processed.

Related Blogs

  • Dr. David Healy

    Dr. David Healy

    Dr. Healy is a professor of psychiatry at Cardiff University in Wales and an author on the history of pharmaceuticals and government regulation.
  • Mad In America: Robert Whitaker

    Mad In America: Robert Whitaker

    Journalist and author Bob Whitaker distills the latest in pharmaceutical and mental health research.
  • Selling Sickness

    Selling Sickness

    Creating a new partnership movement to challenge the selling of sickness.
  • Kathy Brous

    Kathy Brous

    A serial of Kathy's recovery journey as an adult with attachment disorder.
  • Nev Jones

    Nev Jones

    Exploring the intersections of psychiatry, philosophy, neuroscience, cultural theory, critical community psychology and the mad/user/survivor movement.
  • 1boringoldman


    Retired psychiatrist and raconteur offers insightful analysis of the day's events from the woods of Georgia.